NF-кB and IKK as key mediators of inflammation and oncogenic progression

Handbook of Transcription Factor NF-kappaB

Volumn , Issue , 2006, Pages 159-181

  Baldwin, Albert S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878471767     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (136)

1. Marshall, J.S., Mast cell responses to pathogens, Nat. Rev.Immunol., 4, 787, 2004.
2. Greaves, D. and Schall, T., Chemokines and myeloid cell recruitment, Microbes Infect., 2, 331, 2000.
3. Bosca, L. et al., Nitric oxide and cell viability in inflammatory cells: A role for NO in macrophage function and fate, Toxicology, 208, 249, 2005.
4. Kluth, D., Erwig, L., and Rees, A., Multiple facets of macrophages in renal injury, Kidney Int., 66, 542, 2004.
5. Coleman, J.W., Nitric oxide in immunity and inflammation, Int.Immunopharmacol.,1, 1397, 2001.
6. Wilson, H.M. et al., Inhibition of macrophage NF-кB leads to a dominant antiinflammatory phenotype that attenuates glomerular inflammation in vivo, Am. J.Pathol., 167, 27, 2005.
7. Luster, A.D., Chemokines: Chemotactic cytokines that mediate inflammation, N. Engl. J. Med, 338, 436, 1998.
8. Tangirala, R.K., Murao, K., and Quehenberger, O., Regulation of the expression of the human monocyte chemoattractant protein-1 receptor (hCCR2) by cytokines, J. Biol. Chem., 272, 8050, 1997.
9. Tokuyama, H. et al., The simultaneous blockade of chemokine receptors CCR2, CCR5, and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis, Int.Immunol., E-pub ahead of print.
10. Zisman, D.A. et al., MCP-1 protects mice in lethal endotoxemia, J. Clin. Inv., 99, 2832, 1997.
11. Warner, T.D. and Mitchell, J.A., Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic, FASEB J., 18, 790, 2004.
12. Flavell, R.A., The relationship of inflammation and initiation of autoimmune disease: Role of TNF super family members, Curr. Top. Microbiol.Immunol., 266, 1, 2001.
13. Pfeffer, K. et al., Mice deficient for 55kD TNF receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection, Cell, 73, 457, 1993.
14. Leon, L.R., Cytokine regulation of fever: Studies using gene knockout mice, J. Appl. Physiol., 92, 2648, 2002.
15. Dinarello, C., Role of IL-1 receptor antagonist in blocking inflammation mediated by IL-1, New Engl. J. Med, 343, 732, 2000.
16. Peters-Golden, M. et al., Leukotrienes: Underappreciated mediators of innate immune responses, J. Immunol, 174, 589, 2005.
17. Goulding, N.J., The complexity of glucocorticoid actions in inflammation — A four ring circus, Curr. Opin. Pharmacol., 4, 629, 2004.
18. Reimold, A.M., TNFa as therapeutic target: New drugs, more applications, Curr. Drug Targets Inflamm., Allergy 1, 377, 2002.
19. Barnes, PJ., Effects of P2-agonists on inflammatory cells, J. Allergy Clin. Immunol.,104, S10, 1999.
20. McCarey, D.W. et al., Trial of atorvastatin in rheumatoid arthritis: Double-blind, randomized placebo-controlled trial, Lancet, 363, 2015, 2004.
21. Madonna, R. et al., Simvastatin attenuates expression of cytokine-inducible nitric oxide synthase in embryonic cardiac myoblasts, J. Biol. Chem, 280, 13503, 2005.
22. Gilroy, D.W. et al., Inducible cyclooxygenase may have anti-inflammatory properties, Nature Med., 5, 698, 1999.
23. Nencioni, A., Wesselburg, S., and Brossart, P., Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses, Crit. Rev. Immunol., 23, 1, 2003.
24. 2: The anti-inflammatory prostaglandin? Clin.Immunol., 114, 100, 2005.
25. Chadban, S.J. et al., Effect of IL-10 treatment on crescentic glomerulonephritis in rats, Kidney Int., 51, 1809, 1997.
26. Moore, K.M. et al., Interleukin-10 and the interleukin-10 receptor, Ann. Rev. Immunol., 19, 683, 2001.
27. Wilson, H.M. et al., Bone marrow derived macrophages genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis, Mol. Ther., 6, 710, 2002.
28. Matsumoto, K. et al., Different roles for interleukin-10 in onset and resolution of asthmatic responses in allergen-challenged mice, Respirology, 10, 18, 2005.
29. Teder, P. et al., Resolution of lung inflammation by CD44, Science, 296, 155, 2002.
30. Nagaoka, T. et al., Delayed wound healing in the absence of ICAM-1 or L-selectin expression, Am. J. Pathol., 15, 237, 2000.
31. Savill, J., Apoptosis in resolution of inflammation, J. Leukoc. Biol., 61, 375, 1997.
32. Haller, D. et al., TGFP-1 inhibits non-pathogenic Gram negative bacteria-induced NF-кB recruitment to the IL-6 promoter in intestinal epithelial cells through modulation of histone acetylation, J. Biol. Chem., 278, 23851, 2003.
33. De Winter, H. et al., Regulation of mucosal immune responses by IL-10 produced by intestinal epithelial cells in mice, Gastroentrol., 122, 1829, 2002.
34. Leung, D.W. and Bloom, J.W., Update on glucocorticoid action and resistance, J. Allergy Clin. Immunol., 111, 3, 2003.
35. Lawrence, T., Willoughby, D., and Gilroy, D., Anti-inflammatory lipid mediators and insights into the resolution of inflammation, Nat. Rev. Immunol., 2, 787, 2002.
36. Levy, B.D. et al., Lipid mediator class switching during acute inflammation: Signals in resolution, Nature Immunol, 2, 612, 2001.
37. Godson, C. et al., Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages, J. Immunol, 164, 1663, 2000.
38. De Schoolmeester, M.L. et al., Reciprocal effects of IL-4 and interferon-y on immunoglobulin E-mediated mast cell degranulation: A role for nitric oxide but not per-oxynitrite or cyclic GMP, Immunology, 96, 138, 1999.
39. Bingisser, R.M. et al., Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway, J. Immunol, 160, 5729, 1998.
40. Van der Veen, R.C. et al., Antigen presentation to Th1 but not Th2 cells by macrophages results in nitric oxide production and inhibition of T cell proliferation: Interferon-y is essential but insufficient, Cell. Immunol, 20, 125, 2000.
41. Davis, B.J. et al., Nitric oxide inhibits IgE-dependent cytokine production and Fos and Jun activation in mast cells, J. Immunol, 173, 6914, 2004.
42. Nagase, H. and Woessner, J.F., Matrix metalloproteinases, J. Biol.Chem., 274, 21491, 1999.
43. Ramos, C.D. et al., Neutrophil migration induced by IL-8-activated mast cells is mediated by CINC-1, Cytokine, 21, 214, 2003.
44. Fiocchi, C., Inflammatory bowel disease: Etiology and pathogenesis, Gastroenterology, 115, 182, 1998.
45. Podolsky, D.K., Inflammatory bowel disease, New Engl. J. Med., 347, 417, 2002.
46. Kobayashi, K.S. et al., Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract, Science, 307, 731, 2005.
47. Hugot, J.P. et al., Association of Nod2 leucine-repeat variants with susceptibility to Crohn’s disease, Nature, 411, 599, 2001.
48. Suerbaum, S. and Michetti, P., H. pylori infection, N. Engl.J. Med., 347, 1175, 2002.
49. Keates, S. et al., H. pylori infection activates NF-кB gastric epithelial cells, Gastroenterology, 113, 1099, 1997.
50. Munzenmaier, A. et al., A secreted/shed product of H. pylori activates transcription factor NF-кB, J. Immunol, 159, 6140, 1997.
51. Ishihara, S. et al., Essential role of MD2 in TLR4-dependent signaling during H.pylori-associated gastritis, J. Immunol, 173, 1406, 2004.
52. Viala, J. et al., Nod1 responds to peptidoglycan delivery by H.pylori cag pathogenicity island, Nat. Immunol., 5, 1166, 2004.
53. Mokdad, A.H. et al., Prevalence of obesity, diabetes, and obesity-related health risk factors, JAMA, 289, 76, 2003.
54. Hotamisligil, G.S., Inflammatory pathways and insulin action, Int. J. Obes. Relat.Metab. Disord., 27, S53, 2003.
55. Hanahan, D. and Weinberg, R., The hallmarks of cancer, Cell, 100, 57, 2000.
56. Campbell, P.M. and Der, C.J., Oncogenic Ras and its role in tumor cell invasion and metastasis, Semin.Cancer Biol., 14, 105, 2004.
57. Evan, G. and Vousden, K., Proliferation, cell cycle and apoptosis in cancer, Nature,411, 342, 2001.
58. Shay, J.W. and Bacchetti, S., A survey of telomerase activity in human cancer, Eur. J. Cancer, 33, 787, 1997.
59. Johnsen, M. et al., Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation, Curr. Opin. Cell Biol., 10, 667, 1998.
60. Hay, E.D., An overview of epithelio-mesenchymal transformation, Acta Anat., 154, 8, 1995.
61. Thiery, J.P., Epithelial-mesenchymal transitions in tumor progression, Nat. Rev. Cancer, 2, 442, 2003.
62. Coussens, L. and Werb, Z., Inflammation and cancer, Nature, 420, 860, 2002.
63. Turini, M.E. and Dubois, R.N., Cyclooxygenase-2: A therapeutic target, Ann. Rev. Med., 53, 35, 2002.
64. Greten, F.R. et al., IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer, Cell, 118, 285, 2004.
65. Pikarsky, E. et al., NF-кB functions as a tumor promoter in inflammation-associated cancer, Nature, 353, 180, 2004.
66. Clevers, H., At the crossroads of inflammation and cancer, Cell, 118, 671, 2004.
67. Rutter, M. et al., Severity of inflammation is a risk for colorectal neoplasia in ulcerative colitis, Gastroenterology, 126, 451, 2004.
68. Bissell, M. and Radisky, D., Putting tumors in context, Nat. Rev. Cancer, 1, 46, 2001.
69. Balkwill, F., Charles, K., and Mantovani, A., Smoldering and polarized inflammation in the initiation and promotion of malignant disease, Cancer Cell, 7, 211, 2005.
70. Sparmann, A. and Bar-Sagi, D., Ras-induced IL-8 expression plays a critical role in tumor growth and angiogenesis, Cancer Cell, 6, 447, 2004.
71. Alcamo et al., Targeted mutation of the TNF receptor 1 rescues the RelA-deficient mouse and reveals a critical role for NF-кB in leukocyte recruitment, J.Immunol.,167, 1592, 2001.
72. Grigoriadis, G. et al., The Rel subunit of NF-КB-like transcription factors is a positive and negative regulator of macrophage gene expression: Distinct roles for Rel in different macrophage populations, Embo J, 15, 7099, 1996.
73. Grossmann, M. et al., The combined absence of the transcription factor Rel and RelA leads to multiple hemopoietic cell defects, Proc. Nat. Acad. Sci. USA, 96, 11848, 1999.
74. Lawrence, T. et al., Possible new role for NF-кB in the resolution of inflammation, Nat. Med, 7, 1291, 2001.
75. Lai, W.C. et al., Differential regulation of LPS-induced MMP-1 and MMP-9 by p38 and ERK1/2 mitogen-activated protein kinases, J. Immunol, 170, 6244, 2003.
76. Lu, Y. and Wahl, L., Production of MMP-9 by activated monocyes involves a PI3K/Akt/IKKα/NF-кB pathway, J. of Leuk. Biol, 78, 1, 2005.
77. Poligone, B. and Baldwin, A.S., Positive and negative regulation of NF-кB by Cox-21 Roles of different prostaglandins, J. Biol. Chem., 276, 38658, 2001.
78. Anthonsen, M.W., Solhaug, A., and Johansen, B., Functional coupling between secretory and cytosolic phospholipase A2 modulates TNFα- and IL-1β-induced NF-кB activation, J. Biol. Chem., 276, 30527, 2001.
79. Cheah, F.C. et al., Detection of apoptosis by caspase-3 activation in tracheal aspirate neutrophils from premature infants: Relationship with NF-кB activation, J.Leuk. Biol, 77, 432, 2005.
80. Taneja, R. et al., Delayed neutrophil apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane potential and reduced caspase-9 activity, Crit.Care Med., 32, 1460, 2004.
81. Ward, C. et al., Regulation of granulocyte apoptosis by NF-кB, Biochem. Soc. Trans.,32, 465, 2004.
82. Gewirtz, A.T. et al., Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression, J. Immunol., 15, 1882, 2001.
83. Neish, A.S. et al., Prokaryotic regulation of epithelial responses by inhibition of IкBα ubiquitination, Science, 289, 1560, 2000.
84. Kelly, D. et al., Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPARγ and RelA, Nat. Immunol., 5, 104, 2004.
85. Castrillo, A. et al., Inhibition of IKK and IкB phosphorylation by 15d-PGJ2 in activated murine macrophages, Mol. Cell. Biol., 20, 1692, 2000.
86. Rossi, A. et al., Anti-inflammatory cyclopentonone prostaglandins are direct inhibitors of IkB kinase, Nature, 403, 103, 2000.
87. Schottelius, A. et al., Interleukin-10 signaling blocks IkB kinase activity and NF-кB DNA binding, J.Biol. Chem, 274, 1868, 1999.
88. Reynaert, N.L. et al., Nitric oxide represses IкB kinase through S-nitrosylation, Proc. Nat. Acad. Sci. USA, 101, 1845, 2004.
89. Wilson, H.M. et al., Inhibition of macrophage NF-кB leads to a dominant antiinflammatory phenotype that attenuates glomerular inflammation in vivo, Am. J. Pathol., 167, 27, 2005.
90. Arkan, M. et al., IKKβ links inflammation to obesity-induced insulin resistance, Nat. Med, 11, 191, 2005.
91. Cai, M. et al., Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-кB, Nat. Med, 11, 181, 2005.
92. Chen, L.W. et al., The two faces of IKK and NF-кB inhibition: Prevention of systemic inflammation but increased local injury following ischemia-reperfusion, Nat. Med.,9, 575, 2002.
93. Maeda, S. et al., IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis, Cell, 121, 977, 2005.
94. Firestein, G.S., NF-кB: Holy grail for rheumatoid arthritis?, Arthr. Rheum., 50, 2381, 2004.
95. Miagkov, A.V. et al., NF-кB activation provides the potential link between inflammation and hyperplasia in the arthritic joint, Proc. Nat. Acad. Sci. USA, 95, 13859, 1998.
96. Jimi, E. et al., Selective inhibition of NF-кB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo, Nat. Med, 10, 617, 2004.
97. Catley, M.C. et al., Validation of IKKβ as a therapeutic target in airway inflammation disease by adenoviral delivery of dominant negative IKKβ to pulmonary epithelial cells, Br. J. Pharmacol., 145, 114, 2005.
98. Kopp, E. and Ghosh, S., Inhibition of NF-кB by sodium salicylate and aspirin, Science, 270, 2017, 1994.
99. Yin, M.J., Yamamoto, Y., and Gaynor, R.B., The anti-inflammatory agents aspirin and salicylate inhibit the activity of IKKβ, Nature, 396, 15, 1998.
100. Takada, Y. et al., Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-кB activation, inhibition of Cox-2 and cyclin D1, and abrogation of tumor cell proliferation, Oncogene, 23, 9247, 2004.
101. Farmer, P. and Pugin, J., P2-adrenergic agonists effect their anti-inflammatory effects on monocytic cells through the IkB/NF-кB pathway, Am. J.Physiol. Lung Cell. Mol. Physiol., 279, L615, 2000.
102. Lawrence, T. et al., IKKα limits macrophage NF-кB activation and contributes to the resolution of inflammation, Nature, 434, 1238, 2005.
103. Baldwin, A.S., Control of oncogenesis and cancer therapy resistance by the transcription factor NF-кB, J. Clin. Inv., 107, 241, 2001.
104. Karin, M. et al., NF-кB in cancer: From innocent bystander to major culprit, Nat. Rev. Cancer, 2, 301, 2002.
105. Pianetti, S. et al., Her-2/neu overexpression induces NF-кB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IкBα that can be inhibited by the tumor suppressor PTEN, Oncogene, 20, 1287, 2001.
106. Hanson, J.L. et al., NF-кB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation, Cancer Res, 64, 7248, 2004.
107. Reuther, J.Y. et al., A requirement for NF-кB in Bcr-Abl-mediated transformation, Genes Dev., 12, 968, 1998.
108. Zhou, H., Du, M., and Dixit, V.M., Constitutive NF-кB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity, Cancer Cell, 7, 425, 2005.
109. Rocha, S. et al., Regulation of NF-кB and p53 through activation of ATR and Chk1 by the ARF tumor suppressor, Embo J., 24, 1157, 2005.
110. Kim, J.H. et al., Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes, Nature, 434, 921, 2005.
111. Biswas, D.K., EGF-induced NF-кB activation: A major pathway of cell-cycle progression in estrogen receptor negative breast cancer cells, Proc. Nat. Acad. Sci., USA,97, 8542, 2000.
112. Sitcheran, R. et al., Positive and negative regulation of EAAT2 by NF-кB: A role for N-myc in TNF-controlled gene repression, Embo J, 24, 510, 2005.
113. Dajee, M. et al., NF-кB blockade and oncogenic Ras trigger invasive human epidermal neoplasia, Nature, 421, 639, 2003.
114. Zhang, J.Y. et al., NF-кB RelA opposes epidermal proliferation driven by TNFR1 and JNK, Genes Dev, 18, 17, 2004.
115. Ryan, K.M. et al., Role of NF-кB in p53-mediated programmed cell death, Nature,404, 892, 2000.
116. Deng, J. et al., P-catenin interacts with and inhibits NF-кB in human colon and breast cancer, Cancer Cell, 2, 323, 2002.
117. Perkins, N.D., NF-кB: Tumor promoter or suppressor, Trends Cell Biol., 14, 64, 2004.
118. Lam, L.T. et al., Small molecule inhibitors of IKKs are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling, Clin. Cancer Res, 11, 28, 2005.
119. Mayo, M.W. et al., Requirement of NF-кB activation to suppress p53-independent apoptosis induced by oncogenic Ras, Science, 278, 1812, 1997.
120. Bargou, R.C. et al., Constitutive nuclear NF-КB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells, J. Clin. Inv, 100, 2961, 1997.
121. Hinz, M. et al., Constitutive NF-кB maintains high expression of a characteristic gene network, including CD40 and CD86, and a set of anti-apoptotic genes in Hodgkin/Reed-Sternberg cells, Blood, 97, 2798, 2001.
122. Hu, M.C. et al., IKKβ promotes tumorigenesis through inhibition of forkhead Foxo3a, Cell, 117, 225, 2004.
123. Nakanishi, C. and Toi, M., NF-кB inhibitors as sensitizers to anticancer drugs, Nat. Revs. Cancer, 5, 297, 2005.
124. Wang, C.Y. et al., Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-кB, Nat. Med, 5, 412, 1999.
125. Campbell, K., Rocha, S., and Perkins, N., Active repression of antiapoptotic gene expression by RelA/p65 NF-кB, Mol. Cell, 13, 853, 2004.
126. Albanese, C. et al., IKKa regulates mitogenic signaling through transcriptional induction of cyclin D1 via TCF, Mol. Cell. Biol, 14, 285, 2003.
127. Cao, Y. et al., IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development, Cell, 107, 763, 2001.
128. Jung, Y.J. et al., IL-1β-mediated upregulation of HIF-1α via an NF-кB/COX-2 pathway identifies HIF-1α as a critical link between inflammation and oncogenesis, FASEB J., 17, 2115, 2003.
129. Lee, H. et al., Role of Rel-related factors in control of c-myc transcription in receptor-mediated apoptosis of the murine B-cell WEHI cell line, J. Exp. Med, 181, 1169, 1995.
130. Wu, C.Y. et al., H. pylori promote gastric cancer cell invasion through NF-кB and COX-2-mediated pathways, World J. Gastroenterol., 11, 3197, 2005.
131. Muerkoster, S. et al., Tumor stroma interactions and chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and IL-1β, Cancer Res., 64, 1331, 2004.
132. Huber, M.A. et al., NF-кB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression, J. Clin. Inv, 114, 569, 2004.
133. Li, Q., Withoff, S. and Verma, I.M., Inflammation-associated cancer: NF-кB is the lynchpin, Trends in Immunol., 26, 318, 2005.
134. Konturek, P.C. et al., Activation of NF-кB represents the central event in the neoplastic progression associated with Barrett’s esophagus: A possible link to inflammation and overexpression of PPARγ and growth factors, Dig. Dis. Sci., 49, 1075, 2004.
135. Akiyama, M. et al., NF-кB mediates TNFa-induced nuclear translocation of telomerase reverse transcriptase protein, Cancer Res., 63, 18, 2003.
136. Shisodia, S. et al., Cox-2 inhibitor celecoxib abrogates TNF-induced NF-кB activation through inhibition of activation of IкB kinase and Akt in human non-small cell lung carcinoma: Correlation with suppression of COX-2 synthesis, J.Immunol, 173, 2011, 2004.